Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Treating venous thromboembolism: enoxaparin.

Perry DJ.

Hosp Med. 2001 Dec;62(12):757-64. Review.

PMID:
11810736
2.

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW; Matisse Investigators..

J Thromb Haemost. 2007 Jun;5(6):1191-4.

3.

Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.

Huse DM, Cummins G, Taylor DC, Russell MW.

Am J Manag Care. 2002 Jan;8(1 Suppl):S10-6.

5.

Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews.

Krishnan JA, Segal JB, Streiff MB, Bolger DT, Eng J, Jenckes MW, Tamariz LJ, Bass EB.

Respir Med. 2004 May;98(5):376-86. Review.

PMID:
15139566
6.

Management of venous thromboembolism: a systematic review for a practice guideline.

Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB.

Ann Intern Med. 2007 Feb 6;146(3):211-22. Epub 2007 Jan 29. Review. Erratum in: Ann Intern Med. 2007 Mar 6;146(5):396. Hoffman, Lawrence V [corrected to Hofmann, Lawrence V].

PMID:
17261856
7.

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.

van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.

Thromb Haemost. 2009 Apr;101(4):762-9.

PMID:
19350123
8.

[Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].

Prandoni P, Simioni P, Pagnan A.

Minerva Cardioangiol. 2003 Aug;51(4):361-71. Italian.

9.

Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs.

Segal JB, Bolger DT, Jenckes MW, Krishnan JA, Streiff MB, Eng J, Tamariz LJ, Bass EB.

Am J Med. 2003 Sep;115(4):298-308. Review.

PMID:
12967695
10.

Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.

Imberti D, Vallisa D, Anselmi E, Moroni CF, Bertè R, Lazzaro A, Bernuzzi P, Arcari AL, Cavanna L.

Tumori. 2004 Jul-Aug;90(4):390-3.

PMID:
15510981
11.

Review of enoxaparin and its clinical applications in venous and arterial thromboembolism.

Turpie AG, Mason JA.

Expert Opin Pharmacother. 2002 May;3(5):575-98. Review. Erratum in: Expert Opin Pharmacother 2002 Aug;3(8):1233.

PMID:
11996636
12.

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.

Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG.

Blood Coagul Fibrinolysis. 2003 Jun;14(4):341-6.

PMID:
12945875
13.

Low-molecular-weight heparin for initial treatment of venous thromboembolism.

Brewer D.

Am Fam Physician. 2005 Jul 1;72(1):75-6. Review. No abstract available.

14.
15.
16.

Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.

Doggrell SA.

Expert Opin Pharmacother. 2002 Apr;3(4):455-7. Review.

PMID:
11934350
17.

Reimbursement for outpatient therapy with enoxaparin.

Dhamecha A, Yaron J.

Case Manager. 2002 Sep-Oct;13(5):56-60; quiz 61. No abstract available.

PMID:
12239515
19.

Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.

Carroll DN, Hudson EB.

Ann Pharmacother. 2003 Sep;37(9):1194-6.

PMID:
12921498
20.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033

Supplemental Content

Support Center